Websites that market personalized cancer care services often overemphasize their purported benefits and downplay their limitations, and many sites offer genetic tests whose value for guiding cancer treatment has not been shown to be clinically useful, according to a new study from Dana-Farber Cancer Institute.

Dana-Farber researchers have used a novel combination of two oral targeted drugs to dramatically slow the growth of glioblastoma brain tumors in mice, which significantly extended the animals’ survival.

A study led by researchers at Dana-Farber Cancer Institute and Broad
Institute of the Massachusetts Institute of Technology and Harvard
University provides the first demonstration of a practical method of
screening tumors for cancer-related gene abnormalities that might be
treated with "targeted" drugs.

Deprived of androgen hormones, the receptor finds an alternative genetic
pathway to continue growth of prostate cancer cells. An understanding
of this behavior could lead to new therapies targeting specific genes.

A new discovery by Jean Zhao, PhD, and colleagues may help physicians predict which tumors are likely to become resistant to a given drug. In the report, published by Nature Medicine, researchers described how they created a genetically engineered mouse model of human breast cancer in which the most frequently occurring breast cancer oncogene, PIK3CA, could be turned on and off.

A new study by researchers at Dana-Farber Cancer Institute shows a half-day educational program can help women successfully deal with side effects of ovary removing surgery as a cancer prevention measure.